# FORM 7

# **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: _	Australis Capital Inc.	(the "Issuer").			
Trading Symbol:	AUSA				
Number of Outstanding Listed Securities: 276,068,880					
Date: <u>April 4, 2022</u>					

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced, and non-promotional.

# **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact

On March 1, 2022, the Company filed its results for the Company's fiscal 3<sup>rd</sup> quarter 2022. With over 2,400% YoY revenue growth, management believes the results show the impact of its transition from investment to operating company. In its release, the Company shared a general overview of its progress, which has been documented extensively in prior Form 7 reports.

On March 21, 2022, the Company provided an update on its progress in Thailand, where AUDACIOUS has a partnership with Golden Triangle Holdings (GTH). The Company announced that its partner had opened its first cannabis clinic, which is licensed to prescribe medial cannabis for patient treatment. The new clinic, Herbidus, already attracted close to 800 patients since its soft launch, with continued growth anticipated.

2. Provide a general overview and discussion of the activities of management.

Management continues to pursue new strategic opportunities to create shareholder value.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

## None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

#### None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

#### None

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

### None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

#### None.

8. Describe the acquisition of new customers or loss of customers.

#### None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

## None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

## None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

## None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds (1)
Common	224,539	Stock component of	Stock-based
Shares		consideration paid to	Compensation
		Jason Dyck	
Common	33,108	Vesting of Restricted	Stock-based
Shares		Stock Units	Compensation

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers, or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer continues to closely monitor changing guidance issued by state and federal authorities in response to the COVID-19 pandemic. As of the end of March, there have been no changes to capital investment plans nor corporate objectives of the Issuer, nor does the Issuer foresee said changes soon, as a result of the pandemic. Overall, the issuer anticipates the impact of the pandemic to the Issuer's operations to be relatively minimal.

# **Certificate Of Compliance**

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 7 Monthly Progress Report is true.

Dated	April 4, 2022	
		Jon Paul
		Name of Director or Senior Officer
		"Jon Paul"
		Signature CFO
		Official Capacity

Issuer Details Name of Issuer	For Month End	Date of Report		
Australis Capital Inc	February 2022	22/03/07		
Issuer Address 376 East Warm Springs Road, Suite 190				
City/Province/Postal Code Las Vegas, NV 89119	Issuer Fax No. ( )	Issuer Telephone No. (800) 898-0648		
Contact Name Jon Paul	Contact Position Chief Financial Officer	Contact Telephone No. <b>(847) 372-1963</b>		
Contact Email Address jon@audacious.net	Web Site Address www.ausa-corp.com			